Veru's CEO Mitch Steiner on Enobosarm's value-added to the booming GLP-1 Weight Loss Drug Market episode artwork

EPISODE · Oct 13, 2025 · 21 MIN

Veru's CEO Mitch Steiner on Enobosarm's value-added to the booming GLP-1 Weight Loss Drug Market

from WTR Small-Cap Spotlight

Send us Fan MailWe welcome back Veru's CEO Mitch Steiner to our latest WTR Small-Cap Spotligh podcast. In this podcast, Steiner gives us his thoughts on the latest trends in the rapidly evolving GLP-1 market for weight loss, discusses the data from enobosarm's Phase 2b data, and explains  Veru's obesity drug development strategy in the wake of its recent positive interactions with the FDA.

Episode metadata supplied by the publisher feed · Published Oct 13, 2025

Embed this episode

Ready to play

Veru's CEO Mitch Steiner on Enobosarm's value-added to the booming GLP-1 Weight Loss Drug Market

0:00 21:35

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of WTR Small-Cap Spotlight?

This episode is 21 minutes long.

When was this WTR Small-Cap Spotlight episode published?

This episode was published on October 13, 2025.

Can I download this WTR Small-Cap Spotlight episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!